sr 33557 has been researched along with fluvoxamine in 1 studies
| Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (fluvoxamine) | Trials (fluvoxamine) | Recent Studies (post-2010) (fluvoxamine) |
|---|---|---|---|---|---|
| 50 | 3 | 1 | 2,051 | 518 | 434 |
| Protein | Taxonomy | sr 33557 (IC50) | fluvoxamine (IC50) |
|---|---|---|---|
| D | Rattus norvegicus (Norway rat) | 0.54 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.0038 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.54 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.54 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.1 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.54 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
1 other study(ies) available for sr 33557 and fluvoxamine
| Article | Year |
|---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |